Market News & Trends
Lonza & ALSA Ventures Collaborate to Provide Development & Manufacturing Services for Biotech Firms
ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, recently…
Biogen & MedRhythms to Develop & Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
Biogen Inc. and MedRhythms have recently entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment…
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
Entera Bio Ltd. recently announced it recently filed multiple US patent applications to further strengthen the company’s patent protection and support future developments. These patent…
A New Era of Manufacturing: SCHOTT Announces Double-Digit Million Euro Investment in Ready-to-Use Cartridge Production
The international technology group SCHOTT plans to significantly expand its production capacity of ready-to-use (RTU) cartridges. This drug containment and delivery solution is used….
Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on global net sales of products….
Adial Pharmaceuticals Announces Research Collaboration With UC San Diego
Adial Pharmaceuticals, Inc. recently announced Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major….
Novartis' Kymriah Receives EC Approval as First CAR-T Cell Therapy for Adults With Relapsed or Refractory Follicular Lymphoma
Novartis recently announced the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Owen Mumford & Stevanato Group Sign Exclusive Collaboration Agreement for the Innovative Aidaptus Auto-Injector
Owen Mumford Ltd recently signed an exclusive agreement that makes Stevanato Group an exclusive manufacturing partner for the Owen Mumford designed auto-injector, offering a full set of capabilities to its….
Compass Therapeutics Reports Positive Interim Phase 2 Data
Compass Therapeutics, Inc. recently reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers…
EyePoint Pharmaceuticals Announces Expanded License Agreement With Betta Pharmaceuticals
EyePoint Pharmaceuticals, Inc. recently announced the execution of a license agreement with Betta Pharmaceuticals Co. Ltd. to develop and commercialize EYP-1901 in Mainland China, Hong…
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients With Alzheimer’s Disease
BioXcel Therapeutics, Inc. recently announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the company’s proprietary, orally dissolving…
DepYmed Receives FDA Rare Pediatric Disease & Orphan Drug Designations for its Lead Clinical Candidate for the Treatment of Rett Syndrome
DepYmed Inc. recently announced that the US FDA has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule…
Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant in Phase 2b NASH Trial
Hepion Pharmaceuticals, Inc. recently announced it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for…
Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products
Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical development, has launched Apisolex, a novel solubility-enhancing excipient for use in….
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
Nevakar Injectables Inc. recently announced it has entered into an asset sale agreement with Endo Ventures Limited, a subsidiary of Endo International plc (Endo) for the sale of six of its….
Rancho Biosciences Launches the Single Cell Data Science Consortium With Four Charter Members
Rancho Biosciences recently announced the launch of its Single Cell Data Science (SCDS) pre-competitive consortium. The 3-year effort is supported in collaboration with the following…
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity, Inc. recently announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the US FDA for the treatment of Alzheimer’s disease…..
Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced the presentation of new data supporting the potential for setmelanotide to treat the early onset obesity, hyperphagia, and metabolic impairment…
FDA Has Granted Veru a Pre-Emergency Use Authorization Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Veru Inc. recently announced the FDA has granted the company a pre-Emergency Use Authorization (EUA) meeting on May 10, 2022, for the positive Phase 3…
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
Denali Therapeutics Inc. recently announced its partner Sanofi has commenced dosing in a Phase 2 study, named HIMALAYA, of SAR443820 (DNL788) in individuals with amyotrophic…
